Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$18.40 +0.1%	$18.14	$16.10 ▼ $42.47	$2.31B	0.68	2.33 million shs	769,022 shs
AUTL Autolus Therapeutics	$2.31 -0.4%	$1.71	$1.11 ▼ $5.00	$617.45M	1.76	1.57 million shs	1.33 million shs
BHC Bausch Health Cos	$6.43 +0.7%	$5.11	$3.96 ▼ $9.85	$2.36B	0.28	2.61 million shs	2.32 million shs
GMTX Gemini Therapeutics	$53.92 -2.0%	$47.98	$1.16 ▼ $14.10	$2.34B	-0.12	189,291 shs	326,647 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	+0.05%	+3.60%	+8.94%	-24.19%	-54.49%
AUTL Autolus Therapeutics	-0.43%	+12.14%	+47.13%	+39.16%	-31.25%
BHC Bausch Health Cos	+0.71%	+3.75%	+40.13%	-0.93%	-5.38%
GMTX Gemini Therapeutics	-1.97%	+7.64%	+13.82%	+2.75%	+24.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.7552 of 5 stars	4.3	3.0	0.0	4.4	3.5	2.5	0.6
AUTL Autolus Therapeutics	2.6745 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.6
BHC Bausch Health Cos	3.6171 of 5 stars	1.9	2.0	0.0	4.0	3.3	3.3	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	117.68% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	303.46% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	15.43% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AUTL, BHC, GMTX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00
5/8/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $26.00
5/8/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$55.00 ➝ $47.00
5/7/2025	APLS Apellis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.96	N/A	N/A	$1.84 per share	10.00
AUTL Autolus Therapeutics	$10.12M	60.75	N/A	N/A	$1.61 per share	1.43
BHC Bausch Health Cos	$9.63B	0.25	$7.84 per share	0.82	($0.89) per share	-7.22
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.38	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A

Latest AUTL, BHC, GMTX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
AUTL Autolus Therapeutics	N/A	9.24	9.02
BHC Bausch Health Cos	N/A	1.35	0.97
GMTX Gemini Therapeutics	N/A	71.49	71.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
AUTL Autolus Therapeutics	72.83%
BHC Bausch Health Cos	78.65%
GMTX Gemini Therapeutics	75.42%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
AUTL Autolus Therapeutics	25.70%
BHC Bausch Health Cos	8.05%
GMTX Gemini Therapeutics	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable

AUTL, BHC, GMTX, and APLS Headlines

Recent News About These Companies

Gemini Therapeutics (NASDAQ:GMTX) Shares Up 3.6% - Still a Buy?

June 14, 2025 | marketbeat.com

What Is Gemini? Everything You Should Know About Google's AI Tool

October 17, 2024 | cnet.com

Google Gemini could soon get a lot more useful on your phone

July 31, 2024 | androidpolice.comA

Gemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?

July 22, 2024 | businessinsider.com

ChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?

May 23, 2024 | zdnet.comZ

Gemini Monthly Horoscope: May 2024

May 2, 2024 | pedestrian.tvP

Google's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now Supported

April 28, 2024 | techtimes.comT

Comparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmology

April 17, 2024 | ophthalmologytimes.comO

Google's public release of Gemini 1.5 should build trust, Deutsche Bank says

April 17, 2024 | seekingalpha.com

Google takes down Gemini AI image generator. Here’s what you need to know.

February 26, 2024 | washingtonpost.com

‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasco

February 26, 2024 | nypost.comN

Google Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023

December 9, 2023 | androidheadlines.comA

Gemini Review 2023: Pros, Cons and How It Compares

November 16, 2023 | nerdwallet.comN

Yesterday's Gemini Horoscope

October 5, 2023 | yourtango.comY

Gemini Tarot Horoscopes: October 2023

October 3, 2023 | glamour.comG

Yearly Gemini Tarot Card Reading

August 28, 2023 | yourtango.comY

Move over Bard, Google's next big AI product is coming this fall

August 19, 2023 | androidauthority.comA

Radar In Space: The Gemini Rendezvous Radar

July 27, 2023 | hackaday.comH

Sun Transit in Gemini- The twins love the Sun’s visit

July 13, 2023 | prokerala.comP

Sun Transit in Gemini: Sun with Dual energies?

July 5, 2023 | prokerala.comP

Gemini Allows Withdrawals for Voyager Customers Whose Funds Have Been Trapped since Bankruptcy

June 26, 2023 | coinspeaker.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, BHC, GMTX, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$18.40 +0.01 (+0.05%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.40 +0.01 (+0.03%)

As of 08:11 AM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Autolus Therapeutics NASDAQ:AUTL

$2.31 -0.01 (-0.43%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.02 (-0.65%)

As of 08:00 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Bausch Health Cos NYSE:BHC

$6.42 +0.05 (+0.71%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$6.50 +0.07 (+1.09%)

As of 08:04 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Gemini Therapeutics NASDAQ:GMTX

$53.92 -1.09 (-1.97%)

As of 06/25/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time